Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
April 18 2019 - 3:05PM
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage
biopharmaceutical company developing therapies in the Stimulator of
Interferon Genes (STING) and A Proliferation Inducing Ligand
(APRIL) pathways, today announced the appointment of Frank Karbe to
its Board of Directors and Audit Committee. Mr. Karbe, who
currently serves as the chief financial officer of Myovant
Sciences, Inc., brings more than 20 years of life sciences industry
experience to Aduro.
“We are pleased to welcome Frank to our Board as we continue
advancing our STING and APRIL programs through development,” said
Stephen T. Isaacs, chairman, president and chief executive officer
of Aduro. “Frank’s track record of leadership in financial
strategy, operations and corporate development will be a valuable
addition to Aduro.”
“This is an exciting time for Aduro, as its first-in-class STING
agonist and anti-APRIL antibody have the potential to impact the
treatment of multiple oncologic, autoimmune and inflammatory
indications,” added Mr. Karbe. “I look forward to collaborating
with Aduro’s Board and executive leadership team on the company’s
next phase of growth and development.”
Prior to joining Myovant Sciences, a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for women's health and prostate cancer, Mr.
Karbe served as executive vice president and chief financial
officer for Exelixis from 2004 – 2014. Earlier in his career, he
worked as an investment banker for Goldman Sachs & Co., most
recently as vice president in the healthcare group focusing on
corporate finance and mergers and acquisitions in the biotechnology
industry. He also served on the Board of Directors of Arbutus
Biopharma Corporation and Kolltan Pharmaceuticals, Inc. Mr. Karbe
received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate
School of Management, Koblenz, Germany.
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body's natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a fully blocking monoclonal antibody that blocks APRIL
binding to both the BCMA and TACI receptors, is being evaluated in
multiple myeloma and as a potential treatment for IgA nephropathy.
Aduro is collaborating with a number of leading global
pharmaceutical companies to help expand and drive its product
pipeline. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our STING and
APRIL programs for the treatment of cancer, autoimmune and
inflammatory diseases and the value Mr. Karbe will add as a
director. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, early or preliminary clinical trial
results may not be predictive of future results, our history of net
operating losses and uncertainty regarding our ability to achieve
profitability, our ability to develop and commercialize our product
candidates, our ability to use and expand our technologies to build
a pipeline of product candidates, our ability to obtain and
maintain regulatory approval of our product candidates, our ability
to operate in a competitive industry and compete successfully
against competitors that have greater resources than we do, our
reliance on third parties, and our ability to obtain and adequately
protect intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our annual report on Form 10-K for the
year ended December 31, 2018, which is on file with the Securities
and Exchange Commission. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Investor Relations
Contact: |
|
Media
Contact: |
Noopur
Liffick |
|
Aljanae
Reynolds |
510-809-2465 |
|
510-809-2452 |
investors@aduro.com |
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024